Hearing Amplifiers Market Estimated to Register $108.0 Billion and Grow at 5.9% CAGR by 2027 Post the Covid-19 Catastrophe | Declared by Research Dive
21 sept. 2022 09h01 HE
|
Research Dive
New York, USA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global hearing amplifiers market is estimated to register a revenue of $108.0 billion and...
$175.73Mn by 2028 Medical Audiometer Devices Market Size Lead by Hybrid Audiometers (4.4% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
22 nov. 2021 06h42 HE
|
The Insight Partners
New York, Nov. 22, 2021 (GLOBE NEWSWIRE) -- According to our new research study on Medical Audiometer Devices Market Size, Share, Revenue, Forecast to 2028 - COVID-19 Impact and Global Analysis By...
Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update
04 mai 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...
Otonomy Announces Pricing of $30.1 Million Public Offering
07 avr. 2021 22h02 HE
|
Otonomy, Inc.
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy Announces Proposed Public Offering
07 avr. 2021 16h06 HE
|
Otonomy, Inc.
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus
25 mars 2021 07h30 HE
|
Otonomy, Inc.
Phase 2 study design based on successful Phase 1/2 trial including use of Tinnitus Functional Index (TFI) responder analysis for primary efficacy endpointPatient enrollment criteria refined to enrich...
Otonomy to Participate in Three Upcoming Investor Conferences
25 févr. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease
22 févr. 2021 07h00 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
17 févr. 2021 07h30 HE
|
Otonomy, Inc.
Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing lossSupportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection...
Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
11 févr. 2021 16h17 HE
|
Otonomy, Inc.
OTIVIDEX® Phase 3 trial results in Ménière’s disease expected by end of FebruaryOTO-313 Phase 2 trial in tinnitus planned to start in first quarter of 2021 with top-line results expected in...